RetiSpec Competitors

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,500+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai® One is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease. To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas. We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures. A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.

Lunit is a leading provider of AI solutions for cancer diagnostics and therapeutics, with a mission to conquer cancer through AI. Our clinically proven AI enables healthcare providers to detect cancer earlier, make more precise treatment decisions, and improve patient outcomes — transforming how cancer is diagnosed and treated. Our technology spans the entire cancer continuum, from risk prediction and screening optimization to early detection and precision oncology. Lunit’s breast and chest imaging AI boosts diagnostic accuracy and efficiency, while our pathology AI is leveraged by leading pharmaceutical companies to drive biomarker discovery and companion diagnostics (CDx) development. Trusted by 10,000+ sites across 65+ countries, Lunit continues to redefine global standards in data-driven cancer care. Learn more about our technology and mission at www.lunit.io/en